Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 4. Thalidomide for Multiple Myeloma. Figure 12

You Are Here: AHRQ Archive Home > Technology Assessment Archive > Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Figure 12: Comparison of Efficacy

Treatment Types		Newly diagnosed/previously untreated multiple myeloma	Advanced/refractory/resistant multiple myeloma
VBCMP
	Median survival	29 months^24-25	17 months³³
	PPR 50%	72%	13%
VAD
	Median survival	36-44 months^30-31	10-17 months^{31, 33}
	PPR 50%	61-86%	22-70%
Thalidomide only
	Median survival	Estimated 2-year overall survival=96%⁴² Median overall survival not stated	Estimated 2-year overall survival=48% ± 6%⁴³ Median overall survival=5-58 months^{46,51,53,55,58,60}
	Complete response	16-25%	2-9%
	PPR 25%	66-81%	34-100%
	PPR 50%	34-38%^a	8-43%^a
Thalidomide plus dexamethasone
	Median survival	Median overall survival=30 months⁶⁶	Estimated 2-year overall survival=55%⁷⁶ Median OS=7-38 mo^64,69-70,135
	Complete response	8-16%	0-13%
	PPR 25%	54-92%	54-75%
	PPR 50%	17-64%^a	22-55%^a

^aReports of PPR >50% can be misleading.

Return to Document

The information on this page is archived and provided for reference purposes only.